Inato

Inato

Développement de logiciels

Paris, Île-de-France 4 665 abonnés

Matching research sites to the right clinical trial protocols, unlocking site potential worldwide.

À propos

At Inato, our mission is to bring clinical trials to each and every patient, regardless of who they are or where they live. Today, with 5% of sites running 70% of clinical trials, only patients with privileged access to these sites have an opportunity to participate in trials. We envision a world where it’s so easy to find and apply for the right trials that the other 95% of sites – often community-based research sites – can play a bigger role and accelerate research. By expanding access, we can make clinical trials more accessible, efficient, and inclusive. That’s why we’ve created a platform that connects global pharmaceutical companies with a broader range of research sites, while ensuring reliable high performance. Our exclusive site profiles, trial application & verification processes, and ongoing support helps sites (at no charge) to get selected and meet enrollment targets, while giving sponsors access to previously untapped patient populations. We’re seeing growing trust in community sites, faster timelines for sponsors and sites, increased patient accessibility, and diversified participation for more inclusive trials. Drug development is a challenging, intellectually complex, and rewarding endeavor. By working together to bring trial access into communities across the globe, we can more efficiently develop treatments that are safe and effective for everyone.

Secteur
Développement de logiciels
Taille de l’entreprise
51-200 employés
Siège social
Paris, Île-de-France
Type
Société civile/Société commerciale/Autres types de sociétés
Fondée en
2016
Domaines
pharmaceutical industry, Healthtech, Software Engineering, Machine learning, AI, Clinical Research, Clinical Research Sites et Feasibility

Lieux

Employés chez Inato

Nouvelles

Pages similaires

Parcourir les offres d’emploi

Financement

Inato 3 rounds en tout

Dernier round

Série A

20 000 000,00 $US

Voir plus d’informations sur Crunchbase